Effective Jan. 1, 2023, we are making the following changes to the Intravitreal Vascular Endothelial Growth Factor (VEGF) Inhibitors class and adding new drugs to the Medicare Part B Step Therapy program.
Changes to the VEGF Inhibitors class include:
We are also adding several drugs to the Part B Step Therapy program effective Jan. 1, including:
As of Jan. 1, 2023, UnitedHealthcare® Medicare Advantage plans in California are no longer excluded from the Step Therapy program.
For questions related to the step therapy program and the corresponding policy, call the Provider Services number on the member’s health care ID card.